Clinical Trials
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Global Trends in R&D 2024: Activity, productivity, and enablers
Annual trend report from the IQVIA Institute for Human Data Science
Feb 22, 2024
Biomedical advances are transforming healthcare globally. The multi-stakeholder ecosystem that enables this progress has been buffeted by the global COVID-19 pandemic and is resetting and refocusing on future opportunities to advance the understanding of human biology and disease, discover and develop new therapeutics, and provide evidence of the clinical value of these innovations — for individual patients, populations, and health systems. By all of the traditional metrics, including funding levels, numbers of trial starts, drug launches, R&D success rates, and many others, it is clear that industry and investors continue to see tremendous value in the vast array of ongoing research programs around the world.
This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others.
Key findings:
- Clinical development productivity rose in 2023, primarily due to improvement in the composite success rate which jumped to 10.8%, the highest since 2018.
- Industry and regulatory adoption of innovative and technology-driven enablers, including use of predictive biomarkers, novel trial design, and digital and decentralized trial methodologies contributed to productivity gains.
- A total of 69 novel active substances (NASs) were launched globally in 2023, 6 more than the prior year, and including 24 first-in-class launches in the U.S.
- Clinical development programs among larger biopharma companies are shifting away from areas such as COVID-19 and immuno-oncology to focus on hot spots in oncology and a range of therapies across large population and rare diseases.
- R&D funding levels and deal activity reset in 2023 following a steep decline from peak levels in 2020-21.
Other findings:
M&A activity has rebounded overall with deal value and deal counts rising, while median deal value dipped for the second year
- M&A deal values rebounded to $140Bn in 2023 from a low in 2022 but have not yet reached the levels seen in 2019 and 2020.
- Similarly, the number of M&A deals have slowly decreased since 2019, with an uptick to 136 deals in 2023.
- Although the median disclosed deal value in 2023 of $175Mn was 42% below the $301Mn in 2021, the aggregate deal value increased driven by some very high value deals.
Total clinical trial starts decreased by 15% in 2023, dipping below pre-pandemic level as COVID-19 trial starts slowed
- Clinical trial starts slowed in 2023, with a 15% decline compared to 2022 and down 22% when compared to 2021, with 32% of the decline driven by COVID-19 trials, which have declined 69% compared to 2021 (Exhibit 9).
- Without these COVID-19 trials, trial starts have slowed to below the pre-pandemic level.
- Phase I had the most declines, with 19% fewer than 2022; Phase II activity decreased by 11% and Phase III had a 15% decline in planned or actual trial starts, matching the overall trend.
A total of 69 novel active substances (NASs) were launched globally in 2023
- A total 69 novel active substances (NASs) launched globally in 2023, indicating a rise of 10% from 2022 additionally representing a return to pre-COVID-19 levels.
- Oncology, neurology, and immunology have had rising shares of new launches in the past five years, with 204 of the 362 launches (56%) compared to 105 of 246 (43%) from 2014 to 2018.
- Infectious diseases, including anti-bacterial, anti-viral, anti-fungal and anti-parasitic treatments, have included novel treatments for HIV, Ebola, and more recently smallpox, and are 11% of NAS launches over the last decade, with some year-to-year variability.
The composite success rate rose to 10.8% in 2023 driven by increases in Phase I, Phase III and regulatory success
- The composite success rate for the pipeline jumped in 2023 to 10.8% across all therapy areas after falling to a 10-year low in 2022, driven by increases in Phase I, Phase III and regulatory success.
- Phase I success rates rose to 48%, a level last seen in 2019.
- Phase III rates rose to 66%, far above the 56% 10-year pre-pandemic average.
Related solutions
Decentralized Trials
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
Therapeutic & Specialty Expertise
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.